Yoko Yoshimaru

402 total citations
16 papers, 61 citations indexed

About

Yoko Yoshimaru is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Yoko Yoshimaru has authored 16 papers receiving a total of 61 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 7 papers in Epidemiology and 6 papers in Oncology. Recurrent topics in Yoko Yoshimaru's work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Liver Disease Diagnosis and Treatment (4 papers) and Hepatitis B Virus Studies (4 papers). Yoko Yoshimaru is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Liver Disease Diagnosis and Treatment (4 papers) and Hepatitis B Virus Studies (4 papers). Yoko Yoshimaru collaborates with scholars based in Japan. Yoko Yoshimaru's co-authors include Motohiko Tanaka, Masakuni Tateyama, Takehisa Watanabe, Yasuhito Tanaka, Takeshi Kawasaki, Yutaka Sasaki, Hiroko Setoyama, Hideaki Naoe, Kentaro Tanaka and Kazuhiro Izumi and has published in prestigious journals such as Cancers, BMC Gastroenterology and Cancer Medicine.

In The Last Decade

Yoko Yoshimaru

12 papers receiving 61 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoko Yoshimaru Japan 6 41 24 16 14 11 16 61
José Luís Montero Álvarez Spain 6 51 1.2× 26 1.1× 18 1.1× 10 0.7× 33 3.0× 10 77
Marko Korenjak Spain 5 54 1.3× 62 2.6× 14 0.9× 8 0.6× 20 1.8× 7 92
Majd B. Aboona United States 5 29 0.7× 51 2.1× 11 0.7× 16 1.1× 7 0.6× 14 69
Raffaella Viganò Italy 7 71 1.7× 44 1.8× 12 0.8× 21 1.5× 18 1.6× 13 105
Carmen Álvarez‐Navascués Spain 4 45 1.1× 42 1.8× 7 0.4× 15 1.1× 10 0.9× 9 71
Alejandro Pita United States 7 44 1.1× 21 0.9× 14 0.9× 3 0.2× 45 4.1× 17 92
Yuwa Ando Japan 5 48 1.2× 10 0.4× 38 2.4× 20 1.4× 5 0.5× 5 68
Danny Orabi United States 7 36 0.9× 31 1.3× 25 1.6× 5 0.4× 29 2.6× 10 91
Jennifer K. Kerner United States 4 13 0.3× 17 0.7× 12 0.8× 7 0.5× 4 0.4× 5 70
Igor Andrašina Slovakia 5 12 0.3× 12 0.5× 12 0.8× 12 0.9× 6 0.5× 12 54

Countries citing papers authored by Yoko Yoshimaru

Since Specialization
Citations

This map shows the geographic impact of Yoko Yoshimaru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoko Yoshimaru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoko Yoshimaru more than expected).

Fields of papers citing papers by Yoko Yoshimaru

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoko Yoshimaru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoko Yoshimaru. The network helps show where Yoko Yoshimaru may publish in the future.

Co-authorship network of co-authors of Yoko Yoshimaru

This figure shows the co-authorship network connecting the top 25 collaborators of Yoko Yoshimaru. A scholar is included among the top collaborators of Yoko Yoshimaru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoko Yoshimaru. Yoko Yoshimaru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Nagaoka, Katsuya, Naoto Kajitani, Yoko Yoshimaru, et al.. (2025). The Role of an Elevated Fibrosis‐4 Index in Neurocognitive Decline and Brain Volume Reduction in Older Adults With Metabolic Dysfunction‐Associated Steatotic Liver Disease. Geriatrics and gerontology international. 25(12). 1903–1910.
2.
Ito, Takanori, Yasuto Takeuchi, Kazuyuki Mizuno, et al.. (2025). A Guide for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Induced Liver Injury. Kanzo. 66(9). 375–387.
3.
Ito, Takanori, Yasuto Takeuchi, Kazuyuki Mizuno, et al.. (2024). Diagnostic guide for immune checkpoint inhibitor‐induced liver injury. Hepatology Research. 54(8). 719–726. 5 indexed citations
4.
Yoshimaru, Yoko, Masahiro Tomita, Kaori Isono, et al.. (2024). The First Successful Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure Caused by Severe Acute Necrotizing Pancreatitis: A Case Report. Transplantation Proceedings. 56(1). 239–243. 1 indexed citations
5.
Ito, Takanori, Yasuto Takeuchi, Kazuyuki Mizuno, et al.. (2024). Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury. Kanzo. 65(6). 268–276. 2 indexed citations
6.
Setoyama, Hiroko, Yoko Yoshimaru, Kentaro Tanaka, et al.. (2023). Role of Regional Core Centers for Liver Disease Management in the Continuity of Activities of Hepatitis Medical Care Coordinators. Kanzo. 64(11). 583–586. 1 indexed citations
7.
Setoyama, Hiroko, Kentaro Tanaka, Takayuki Tokunaga, et al.. (2023). Two cases of acute liver failure complicated by COVID-19 remarkably responded to anticoagulant therapy. Kanzo. 64(6). 270–279.
8.
9.
Tokunaga, Takayuki, Motohiko Tanaka, Kentaro Tanaka, et al.. (2021). Modified albumin–bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients. International Journal of Clinical Oncology. 26(5). 922–932. 7 indexed citations
10.
Tokunaga, Takayuki, Masakuni Tateyama, Kentaro Tanaka, et al.. (2021). Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity. Hepatology Research. 52(1). 105–119. 5 indexed citations
11.
Watanabe, Takehisa, Katsuya Nagaoka, Yoki Furuta, et al.. (2021). Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatology Communications. 6(5). 1198–1212. 5 indexed citations
12.
Nagaoka, Katsuya, Masakuni Tateyama, Hideaki Miyamoto, et al.. (2021). A case of primary hepatic leiomyosarcoma treated with multi-line chemotherapy. Kanzo. 62(9). 538–547.
13.
Tateyama, Masakuni, Hideaki Naoe, Motohiko Tanaka, et al.. (2020). Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study. BMC Gastroenterology. 20(1). 371–371. 11 indexed citations
14.
Sugawara, Yasuhiko, Takehisa Watanabe, Yoko Yoshimaru, et al.. (2016). Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation. BioScience Trends. 10(6). 496–499. 1 indexed citations
15.
Tanaka, Motohiko, Kazuhiro Izumi, Takehisa Watanabe, et al.. (2015). Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Medicine. 4(8). 1214–1223. 18 indexed citations
16.
Watanabe, Takehisa, Yoko Yoshimaru, Takeshi Kawasaki, et al.. (2014). A case of acute hepatitis B on the patient of primary biliary cirrhosis who was registered for the brain-death donor liver transplantation. Kanzo. 55(3). 176–181. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Luís Montero Álvarez Breakdown of academic impact, for papers by Marko Korenjak Breakdown of academic impact, for papers by Majd B. Aboona Breakdown of academic impact, for papers by Raffaella Viganò Breakdown of academic impact, for papers by Carmen Álvarez‐Navascués Breakdown of academic impact, for papers by Alejandro Pita Breakdown of academic impact, for papers by Yuwa Ando Breakdown of academic impact, for papers by Danny Orabi Breakdown of academic impact, for papers by Jennifer K. Kerner Breakdown of academic impact, for papers by Igor Andrašina
Rankless by CCL
2026